Acumen Pharmaceuticals, Inc.

03/26/2026

Today we announced our 2025 Year End Financial Results and Business Highlights.

🔗Click the link to read the full release: https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-reports-financial-results-year-ended-1

03/23/2026

All good things must come to an end, and while the Acumen team is sad to leave , it’s been a wonderful week of sharing knowledge and innovation in the ’s field.

We’ll see you all next year at AD/PD - Advances in Science & Therapy 2027!

03/21/2026

Today at AD/PD - Advances in Science & Therapy, Paul Shughrue, VP, Program Leader and Head of Research, presented new nonclinical findings on our Enhanced Brain Delivery (EBD™), constructs of sabirnetug.

The data highlight efforts to advance AD treatment by improving brain pe*******on of sabirnetug through enhanced brain delivery approaches. These include developing bispecific antibodies that target transferrin receptors to improve drug pe*******on across the blood-brain barrier.

Learn more here: https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-presents-studies-enhanced-brain

03/20/2026

It’s day 4 of and it’s been a great conference so far, filled with insightful conversations and meaningful connections!

Tomorrow we’ll be sharing findings from our nonclinical work evaluating Enhanced Brain Delivery (EBD™) bispecific constructs of sabirnetug and transferrin targeting antibodies, designed to improve brain pe*******on.

📅 Saturday, March 21

⏰ 8:40 – 10:40 a.m. CET

🧠 Session: Restoring Neural Resilience in ALS and Alzheimer's Disease (ID21)

AD/PD - Advances in Science & Therapy

03/19/2026

Putting the spotlight on our posters!

Today, Hugo Vanderstichele presented a poster titled “Sabirnetug Biomarker Treatment Responses: Exploratory Evaluation of the CNS Disease Panel NULISAseq™” at AD/PD - Advances in Science & Therapy.

This poster highlights Acumen’s exploratory use of the NULISAseq™ CNS Disease Panel to evaluate biomarker effects and support future integration of these analyses in ongoing clinical development.

03/18/2026

Putting the spotlight on our posters!

Yesterday, Elizabeth Johnson presented a poster titled “Development and Characterization of Novel Antibodies Targeting Amyloid Beta Oligomers with High Selectivity.”

If you're interested in learning more about the rest of our presentations at AD/PD - Advances in Science & Therapy this year, check out our full press release here: https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-presents-studies-enhanced-brain

03/17/2026

We’re excited to share new research at AD/PD - Advances in Science & Therapy 2026 this week in Copenhagen and online! Our oral and poster presentations highlight progress in enhanced brain delivery (EBD™) for sabirnetug, exploratory biomarker analyses using NULISAseq™, and development of highly selective anti‑AβO antibodies.

If you’re attending AD/PD, we invite you to stop by our presentations and learn more about our latest work.

Learn more in our press release: https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-presents-studies-enhanced-brain

03/16/2026

Today we announced a $35.75 million private placement to advance potential best‑in‑class molecules from our amyloid beta oligomer‑selective Enhanced Brain Delivery (EBD™) portfolio.

This financing strengthens our momentum as we continue developing differentiated, oligomer‑selective candidates designed to more effectively reach the brain and support our long‑term goal of improving the lives of people impacted by Alzheimer’s disease.

We’re grateful for the confidence our investors have placed in our vision and science, and for the dedication of our team and partners who make progress like this possible.

🔗 Press Release: https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-announces-3575-million-private-placement

03/12/2026

The field of Alzheimer’s research is advancing rapidly toward identifying risk earlier and intervening sooner. Acumen’s Chief Medical Officer, Eric Siemers MD, is an author on a newly published paper summarizing the spring 2025 Alzheimer's Association's Research Roundtable discussion, which explored emerging biomarker advances, prevention strategies, and treatment approaches before cognitive symptoms appear.

The meeting report is now available in 'Alzheimer’s & Dementia: Translational Research & Clinical Interventions'.

Read more:

Advances in biomarker technology, digital cognitive assessments, and amyloid-targeting therapies have redefined the opportunities for accurate and early diagnosis and care of Alzheimer's disease (AD...

03/11/2026

At Acumen, we believe in putting people first, and what better way to do that than by shining a spotlight on our incredible team members and the amazing work they do!

March's 'Ask Acumen' featured team member is Yuli Wu, MD, VP, Drug Safety & Pharmacovigilance.

🔗Click the link to get a behind-the-scenes look at Yuli's journey, passions, and outstanding contributions to our mission: https://acumenpharm.com/ask-acumen/

03/03/2026

We’re excited to be attending this year’s AD/PD - Advances in Science & Therapy Conference in Copenhagen. We’re presenting one oral and two poster sessions that highlight our work on enhanced brain delivery (EBD™) and antibody selectivity, advancing how we target toxic Aβ oligomers in Alzheimer’s disease. If you’re attending the conference, check out our presentations.

🔗More details are in the press release: https://investors.acumenpharm.com/news-releases/news-release-details/acumen-pharmaceuticals-showcase-advances-alzheimers-treatment

02/24/2026

Having strong company values is vital to building a positive work culture and driving Acumen's mission forward. We want to share our values with the world in the hope that they may inspire others to join us in making a meaningful impact.

Integrity is a cornerstone of our company culture at Acumen. We believe that by conducting ourselves with honesty and transparency, we can build trust and make a lasting impact in the world. Our commitment to integrity means that we hold ourselves accountable to the highest ethical standards, we strive to create a culture of integrity that extends beyond our organization and inspires others to do the same.